Pipeline

March 11, 2019

Company	Drug/Device	Medical Condition	Status
AOBiome Therapeutics, Inc.	B244	pediatric patients with atopic dermatitis (eczema)	Phase Ib trial initiated enrolling 36 subjects aged 2 to 17 years
Forbius	AVID200	diffuse cutaneous systemic sclerosis (SSc)	Phase Ib trial initiated
I-Mab Biopharma	TJ107 (HyLeukin)	advanced solid tumors	Phase Ib/IIa trial initiated enrolling 58 subjects in China
Odonate Therapeutics, Inc.	tesetaxel	locally advanced or metastatic breast cancer (LA/MBC)	Phase II trial initiated enrolling 125 subjects with human epidermal growth factor receptor 2 (HER2) negative, hormone receptor (HR) positive disease who have not previously received a taxane
Eidos Therapeutics, Inc.	AG10	transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM)	Phase III trial initiated enrolling 510 subjects with symptomatic ATTR-CM, associated with either wild-type or mutant TTR, with New York Heart Association Class I-III symptoms
Inovio	VGX-3100	cervical dysplasia caused by human papillomavirus (HPV)	Phase III trial initiated enrolling adult female subjects with HPV 16/18 positive biopsy-proven cervical HSIL, otherwise known as cervical intraepithelial neoplasia (CIN) 2 or 3
Acceleron Pharma, Inc.	ACE-083	Charcot-Marie-Tooth disease (CMT)	Orphan Drug designation granted by the FDA
Mitochon Pharmaceuticals	MP-101	Huntington’s Disease	Orphan Drug designation granted by the FDA
Celgene Corporation	fedratinib	myelofibrosis	Priority Review granted by the FDA
NKMax America	SNK01	refractory cancer	IND approval granted by the FDA
Breckenridge Pharmaceutical, Inc.	Imatinib Mesylate Tablets	cancer	ANDA approval granted by the FDA
Janssen	Spravato	major depressive disorder	Approval granted by the FDA
Baxter International, Inc.	eptifibatide	acute coronary syndrome (ACS)	Approval granted by the FDA
Adlon Therapeutics, L.P.m	Adhansia XR (methylpheni-date hydrochloride) extended-release capsules CII	Attention-Deficit/Hyperactivity Disorder (ADHD)	Approval granted by the FDA